MedTrace Logo

Vancomycin vs. Vancomycin Plus Gentamycin in Treatment of MRSA Infection

NCT00304811 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2009-09-28

No results posted yet for this study

Summary

The purpose of this study is to compare the outcome of treatment for bacteremic MRSA infection with vancomycin alone, vancomycin plus gentamicin, vancomycin plus rifampin, and vancomycin plus gentamicin and rifampin.

Conditions

  • Staphylococcus Aureus

Interventions

DRUG

Vancomycin

DRUG

Vancomycin plus Gentamicin

DRUG

Vancomycin plus Rifampin

DRUG

Vancomycin plus Gentamicin plus Rifampin

Sponsors & Collaborators

  • Baylor College of Medicine

    collaborator OTHER

  • Michael E. DeBakey VA Medical Center

    lead FED

Principal Investigators

  • Daniel M Musher, MD · Baylor College of Medicine, Houston VA Medical Center

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304811 on ClinicalTrials.gov